BioSpace News Archive

The ASH Research Collaborative and Global Blood Therapeutics, Inc. today announced that GBT will provide a grant of $400,000 to the ASH RC in support of the ASH RC Data Hub Sickle Cell Disease (SCD) program.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators will present data from more than 30 abstracts demonstrating the utility of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay in assessing minimal residual disease (MRD) in blood cancer patients at the 63rd Annual Meeting.

HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, announced today it had licensed exclusive worldwide ex-China rights to the KRAS inhibitor, JMKX1899, from Shanghai Jemincare Pharmaceutical Co., Ltd. Jemincare will retain the relevant rights in the greater China area.

In a study published in Nature genetics, scientists at deCODE genetics, a subsidiary of the pharmaceutical company Amgen, demonstrate how measuring the levels of a large number of proteins in plasma at population scale when combined with data on sequence diversity and RNA expression dramatically increases insights into human diseases and other phenotypes.

Tavros Therapeutics, and OpenBench, today announced a collaboration in which OpenBench will identify novel, potent antagonists against an undisclosed cancer target that was identified by Tavros’s proprietary functional genomics platform.

The ultrasonic electrosurgical devices market has been predicted to grow at a noticeable pace during the forecast period.

ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing novel cell replacement therapies to address diseases with significant unmet needs, announced publication of promising preliminary results of an ongoing, first-in-human Phase 1/2 study demonstrating that its stem cell-derived therapy can produce insulin in people with severe type 1 diabetes (T1D).

Bruker Corporation (Nasdaq: BRKR) today announced that its established CE-IVD marked FluoroType® SARS-CoV-2 varID Q real-time multiplexed PCR assay reliably detects all SARS-CoV-2 variants, and in addition is expected to also provide a clear indication of Omicron (B.1.1.529), recently declared a ‘variant of concern’ by the WHO.